Small Molecule Inhibitors for NOTCH-driven Cancers
Total Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
113
NCT03422679
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 5, 2017
Completion: Nov 11, 2022
NCT04714619
CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Phase: Phase 2
Role: Collaborator
Start: May 6, 2021
Completion: Apr 26, 2022
NCT05774899
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Start: Jun 1, 2023
Completion: Jun 1, 2027
Loading map...